Pacira BioSciences Book Value 2011-2026 | PCRX

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Pacira BioSciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
778 M	870 M	775 M	730 M	620 M	355 M	321 M	279 M	219 M	218 M	171 M	41.2 M	65.9 M	48.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
870 M	41.2 M	392 M

Quarterly Book Value Pacira BioSciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
727 M	758 M	799 M	778 M	750 M	879 M	892 M	870 M	832 M	808 M	768 M	775 M	770 M	-	710 M	730 M	719 M	687 M	651 M	620 M	620 M	620 M	620 M	355 M	355 M	355 M	355 M	321 M	321 M	321 M	321 M	279 M	279 M	279 M	279 M	219 M	219 M	219 M	219 M	218 M	218 M	218 M	218 M	171 M	171 M	171 M	171 M	41.2 M	41.2 M	41.2 M	41.2 M	65.9 M	65.9 M	65.9 M	65.9 M	48.3 M	48.3 M	48.3 M	48.3 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
892 M	41.2 M	401 M

Book Value of other stocks in the Drug manufacturers industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Agile Therapeutics AGRX	-16.3 M	-	10.11 %	$ 58.2 M	USA
AcelRx Pharmaceuticals ACRX	17 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-651 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-17.3 M	-	-	$ 754 M	USA
Catalent CTLT	3.6 B	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	45.2 M	-	-	$ 50.1 M	USA
Alimera Sciences ALIM	46.2 M	-	-	$ 142 M	USA
Athenex ATNX	-24.2 M	-	-23.39 %	$ 1.76 M	USA
Eagle Pharmaceuticals EGRX	234 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	5.14 B	-	-	$ 28.9 M	Irlanda
Avadel Pharmaceuticals plc AVDL	73.8 M	-	-	$ 2.06 B	France
Evoke Pharma EVOK	-2.58 M	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	22.5 M	$ 3.13	1.29 %	$ 44 M	USA
Cronos Group CRON	1.71 B	$ 2.59	0.19 %	$ 1.35 B	Canada
Calliditas Therapeutics AB (publ) CALT	1.46 B	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	314 M	-	2.45 %	$ 38.1 M	Canada
Bausch Health Companies BHC	-82 M	$ 5.73	2.32 %	$ 2.09 B	Canada
Harrow Health HROW	52.1 M	$ 37.01	3.01 %	$ 1.36 B	USA
Aurora Cannabis ACB	609 M	$ 3.51	2.19 %	$ 86.3 M	Canada
Canopy Growth Corporation CGC	487 M	$ 1.09	3.81 %	$ 117 M	Canada
Tilray TLRY	3.33 B	$ 6.72	2.28 %	$ 4.15 B	Canada
OrganiGram Holdings OGI	306 M	$ 1.44	2.5 %	$ 402 M	Canada
Neoleukin Therapeutics NLTX	265 M	-	-	$ 193 M	Canada
Jupiter Wellness JUPW	35 M	-	-	$ 33.6 M	USA
Relmada Therapeutics RLMD	86.5 M	$ 7.36	0.89 %	$ 291 M	USA
Lannett Company LCI	-251 M	-	1.15 %	$ 7.11 M	USA
Veru VERU	32.3 M	$ 2.39	0.42 %	$ 322 M	USA
Viatris VTRS	21.1 B	$ 13.79	2.38 %	$ 16.6 B	USA
Evolus EOLS	-23.1 M	$ 4.31	0.94 %	$ 278 M	USA
Emergent BioSolutions EBS	649 M	$ 8.23	3.39 %	$ 421 M	USA
Sundial Growers SNDL	1.1 B	$ 1.39	-2.11 %	$ 3.37 M	Canada
Organogenesis Holdings ORGO	385 M	$ 2.41	1.26 %	$ 317 M	USA
PetIQ PETQ	868 M	-	1.64 %	$ 400 M	USA
ProPhase Labs PRPH	63.6 M	-	-	$ 5.07 M	USA
Assertio Holdings ASRT	94 M	$ 18.02	-	$ 115 M	USA
cbdMD YCBD	1.96 M	$ 0.73	7.72 %	$ 3.15 M	USA
Radius Health RDUS	-252 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	58.7 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	-86.6 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	49.4 M	$ 1.02	2.5 %	$ 50.9 M	USA
PLx Pharma PLXP	51.7 M	-	-27.8 %	$ 2.56 M	USA
Solid Biosciences SLDB	180 M	$ 8.52	6.23 %	$ 746 M	USA
Sonoma Pharmaceuticals SNOA	4.41 M	$ 2.27	-0.44 %	$ 2.82 M	USA
Zomedica Corp. ZOM	115 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	46.2 M	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	37 M	$ 0.91	0.41 %	$ 32.7 M	USA
Tricida TCDA	218 K	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	22.7 M	$ 0.65	0.62 %	$ 2.79 M	China
TherapeuticsMD TXMD	26.9 M	$ 2.0	-3.38 %	$ 23.1 M	USA